Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) – Equities research analysts at Oppenheimer dropped their FY2023 earnings per share estimates for Aptose Biosciences in a research note issued on Wednesday, March 27th, according to Zacks Investment Research. Oppenheimer analyst M. Biegler now forecasts that the biotechnology company will post earnings of $0.22 per share for the year, down from their prior forecast of $0.23. Oppenheimer currently has a “Outperform” rating and a $6.00 price objective on the stock.
Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last released its earnings results on Tuesday, March 12th. The biotechnology company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01).
NASDAQ APTO traded down $0.02 on Friday, reaching $1.83. 103,226 shares of the stock were exchanged, compared to its average volume of 196,845. Aptose Biosciences has a one year low of $1.57 and a one year high of $4.55. The stock has a market cap of $73.66 million, a price-to-earnings ratio of -2.13 and a beta of 1.61.
In other Aptose Biosciences news, CFO Gregory K. Chow purchased 15,000 shares of Aptose Biosciences stock in a transaction that occurred on Wednesday, March 13th. The shares were bought at an average price of $1.75 per share, for a total transaction of $26,250.00. Following the completion of the transaction, the chief financial officer now owns 122,014 shares of the company’s stock, valued at approximately $213,524.50. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Erich Platzer sold 20,000 shares of the business’s stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $2.19, for a total transaction of $43,800.00. The disclosure for this sale can be found here. In the last quarter, insiders have bought 35,000 shares of company stock worth $63,750.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Noven Financial Group Inc. purchased a new stake in shares of Aptose Biosciences during the fourth quarter valued at $27,000. Geode Capital Management LLC bought a new stake in shares of Aptose Biosciences in the fourth quarter valued at about $33,000. Patriot Financial Group Insurance Agency LLC raised its holdings in shares of Aptose Biosciences by 11.4% in the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 57,429 shares of the biotechnology company’s stock valued at $110,000 after acquiring an additional 5,890 shares in the last quarter. Citadel Advisors LLC bought a new stake in shares of Aptose Biosciences in the third quarter valued at about $125,000. Finally, Virtu Financial LLC bought a new stake in shares of Aptose Biosciences in the first quarter valued at about $198,000. Institutional investors own 7.68% of the company’s stock.
About Aptose Biosciences
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Featured Story: How Do Investors Open a Backdoor Roth IRA?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.